Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694691 · ClinicalTrials.gov registry record · NA
Developing Viability Index for Machine Perfused Livers
A NA study of Liver Cirrhoses, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03694691 is a NA study of Liver Cirrhoses that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03694691, a NA study of Liver Cirrhoses, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collecting biopsies from transplanted livers before and after implantation to correlate metabolite and gene expression with post-transplant function. This data will help develop a viability index for machine perfused livers.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Liver Biopsy
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2030-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694691
The ClinicalTrials.gov registry entry for NCT03694691 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Cirrhoses appearing as the primary indexed condition, and to 1 intervention - of which Liver Biopsy is the first listed.
NCT03694691 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03694691 about?
NCT03694691 is a clinical study titled "Developing Viability Index for Machine Perfused Livers". Machine perfusion technology is nearing the point of rescuing discarded liver grafts in the hope of proving them to be or improving them to the point of being transplantable. However, there are no validated metrics to determine transplantability after machine perfusion. This study involves collectin...
What is the current status of trial NCT03694691?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-10-01. Estimated completion is 2030-06-01.
What conditions does trial NCT03694691 study?
This clinical trial studies the following conditions: Liver Cirrhoses.
What interventions are being tested in trial NCT03694691?
The interventions under investigation include: Liver Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03694691?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03694691 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cirrhoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.